Literature DB >> 23018875

Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer.

Eva Karamitopoulou1, Inti Zlobec, Viktor Kölzer, Agathi Kondi-Pafiti, Efstratios S Patsouris, Konstantin Gennatas, Alessandro Lugli.   

Abstract

Although tumor budding is linked to adverse prognosis in colorectal cancer, it remains largely unreported in daily diagnostic work due to the absence of a standardized scoring method. Our aim was to assess the inter-observer agreement of a novel 10-high-power-fields method for assessment of tumor budding at the invasive front and to confirm the prognostic value of tumor budding in our setting of colorectal cancers. Whole tissue sections of 215 colorectal cancers with full clinico-pathological and follow-up information were stained with cytokeratin AE1/AE3 antibody. Presence of buds was scored across 10-high-power fields at the invasive front by two pathologists and two additional observers were asked to score 50 cases of tumor budding randomly selected from the larger cohort. The measurements were correlated to the patient and tumor characteristics. Inter-observer agreement and correlation between observers' scores were excellent (P<0.0001; intraclass correlation coefficient=0.96). A test subgroup of 65 patients (30%) was used to define a valid cutoff score for high-grade tumor budding and the remaining 70% of the patients were entered into the analysis. High-grade budding was defined as an average of ≥10 buds across 10-high-power fields. High-grade budding was associated with a higher tumor grade (P<0.0001), higher TNM stage (P=0.0003), vascular invasion (P<0.0001), infiltrating tumor border configuration (P<0.0001) and reduced survival (P<0.0001). Multivariate analysis confirmed its independent prognostic effect (P=0.007) when adjusting for TNM stage and adjuvant therapy. Using 10-high-power fields for evaluating tumor budding has independent prognostic value and shows excellent inter-observer agreement. Like the BRE and Gleason scores in breast and prostate cancers, respectively, tumor budding could be a basis for a prognostic score in colorectal cancer.

Entities:  

Mesh:

Year:  2012        PMID: 23018875     DOI: 10.1038/modpathol.2012.155

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  58 in total

Review 1.  Tumour budding in colorectal cancer: what do we know and what can we do?

Authors:  Linde De Smedt; Sofie Palmans; Xavier Sagaert
Journal:  Virchows Arch       Date:  2015-11-27       Impact factor: 4.064

2.  IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage.

Authors:  Qingzhu Wei; Xiaoping Huang; Bo Fu; Jianghuan Liu; Ling Zhong; Qiao Yang; Tong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2015-09       Impact factor: 9.410

4.  Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study.

Authors:  Viktor H Koelzer; Inti Zlobec; Martin D Berger; Gieri Cathomas; Heather Dawson; Klaus Dirschmid; Marion Hädrich; Daniel Inderbitzin; Felix Offner; Giacomo Puppa; Walter Seelentag; Beat Schnüriger; Luigi Tornillo; Alessandro Lugli
Journal:  Virchows Arch       Date:  2015-02-21       Impact factor: 4.064

5.  Prognostic value of tumor budding in gallbladder cancer: application of the International Tumor Budding Consensus Conference scoring system.

Authors:  Han-Na Kim; Soo Yeon Lee; Baek-Hui Kim; Chung-Yeul Kim; Aeree Kim; Hayeon Kim
Journal:  Virchows Arch       Date:  2021-01-04       Impact factor: 4.064

6.  Prognostic Significance of Lacunarity in Preoperative Biopsy of Colorectal Cancer.

Authors:  Gorana Aralica; Martina Šarec Ivelj; Arijana Pačić; Josip Baković; Marija Milković Periša; Anteja Krištić; Paško Konjevoda
Journal:  Pathol Oncol Res       Date:  2020-07-02       Impact factor: 3.201

Review 7.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Authors:  Alessandro Lugli; Richard Kirsch; Yoichi Ajioka; Fred Bosman; Gieri Cathomas; Heather Dawson; Hala El Zimaity; Jean-François Fléjou; Tine Plato Hansen; Arndt Hartmann; Sanjay Kakar; Cord Langner; Iris Nagtegaal; Giacomo Puppa; Robert Riddell; Ari Ristimäki; Kieran Sheahan; Thomas Smyrk; Kenichi Sugihara; Benoît Terris; Hideki Ueno; Michael Vieth; Inti Zlobec; Phil Quirke
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

8.  Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.

Authors:  Shigenobu Tatsumi; Hiroshi Matsuoka; Yumi Hashimoto; Kohei Hatta; Kotaro Maeda; Shingo Kamoshida
Journal:  Int J Clin Exp Pathol       Date:  2013-12-09

9.  Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome.

Authors:  Viktor H Koelzer; Katharina Canonica; Heather Dawson; Lena Sokol; Eva Karamitopoulou-Diamantis; Alessandro Lugli; Inti Zlobec
Journal:  Oncoimmunology       Date:  2015-11-09       Impact factor: 8.110

10.  Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Kaitlin M Woo; Camelia S Sima; David J Finley; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.